Amphastar Pharmaceuticals (AMPH) EBT Margin (2013 - 2026)

Amphastar Pharmaceuticals has reported EBT Margin for 14 years, with the latest figure at 20.96% in Q2 2026.

• On a quarterly basis, EBT Margin fell 159.0% year-over-year to 20.96% in Q2 2026; TTM through Jun 2026 was 14.71%, a 844.0% decrease from a year earlier, with the FY2025 full-year figure at 17.91%, down 875.0% from the prior year.
• EBT Margin was 20.96% for Q2 2026 at Amphastar Pharmaceuticals, up from 5.87% in the prior quarter.
• The five-year high for EBT Margin was 38.83% in Q4 2022, with the low at 5.87% in Q1 2026.
• Average EBT Margin over 5 years is 23.18%, with a median of 23.26% recorded in 2023.
• The largest YoY upside for EBT Margin was 1916 bps in 2022 against a maximum downside of 1474 bps in 2022.
• Over 5 years, EBT Margin stood at 38.83% in 2022, then retreated by 25 bps to 29.14% in 2023, then fell by 9 bps to 26.47% in 2024, then dropped by 23 bps to 20.34% in 2025, then advanced by 3 bps to 20.96% in 2026.
• The last three EBT Margin figures came in at 20.96% (Q2 2026), 5.87% (Q1 2026), and 20.34% (Q4 2025), per Business Quant data.